Literature DB >> 3443056

Is hypertension treated adequately?

L Hansson1, J I Robertson.   

Abstract

In hypertensive patients, morbidity and mortality from the malignant phase, stroke, left ventricular failure, coronary disease and progressive renal failure are closely linked to the level of blood pressure. This relationship between blood pressure and risk can be demonstrated also when blood pressure is lowered with antihypertensive agents. Thus, it appears that the treated blood pressure level is a much stronger indicator of prognosis than is the initial untreated value. However, in the last 2 years, 3 large scale studies have shown that morbidity and mortality in treated hypertensive patients are still considerably higher than expected and significantly greater than in comparable normotensive subjects or control populations. There could be several explanations for these disturbing findings. One is that long-standing hypertension may cause irreversible cardiovascular changes that continue to put such individuals at risk, even after their blood pressure has been brought under control. Another possibility is that the pharmacological agents used in the treatment of hypertension may have some partially adverse effects in addition to their beneficial action on blood pressure. For example, drug-induced changes in serum lipids or of serum electrolytes could somewhat offset the advantages from blood pressure reduction. Furthermore, less than optimal control of elevated blood pressure could be a factor. It is worth noting that consistent arterial pressure reduction has been achieved in only a fraction of treated patients in the large scale intervention trials.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3443056     DOI: 10.2165/00003495-198700343-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  23 in total

1.  Some aspects of prognosis in treated hypertension.

Authors:  M J NEWMAN; J I ROBERTSON
Journal:  Br Med J       Date:  1959-05-30

2.  Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.

Authors: 
Journal:  JAMA       Date:  1970-08-17       Impact factor: 56.272

3.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

4.  Re-examination of some of the Framingham blood-pressure data.

Authors:  T W Anderson
Journal:  Lancet       Date:  1978-11-25       Impact factor: 79.321

5.  Cardiac involvement in hypertension. A non-invasive study of patients with previous malignant hypertension and 'benign' hypertension.

Authors:  T Gudbrandsson; R Sivertsson; H Herlitz; L Hansson
Journal:  Eur Heart J       Date:  1982-06       Impact factor: 29.983

6.  Strategy of prevention: lessons from cardiovascular disease.

Authors:  G Rose
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-06

7.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

8.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

9.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

10.  The Australian therapeutic trial in mild hypertension. Report by the Management Committee.

Authors: 
Journal:  Lancet       Date:  1980-06-14       Impact factor: 202.731

View more
  1 in total

1.  Isradipine dose-confirmation study in Filipino patients with mild to moderate hypertension.

Authors:  R F Abarquez; E I Cabral; E P Namin; H B Calleja; C I Porciuncula; R A Divinagracia; R V Anastacio; R R Castillo
Journal:  Drugs       Date:  1990       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.